Scholar Rock (NASDAQ:SRRK) Given “Outperform” Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Scholar Rock (NASDAQ:SRRK) in a research report released on Tuesday,RTT News reports. The firm currently has a $50.00 target price on the stock.

Several other equities analysts also recently commented on the company. HC Wainwright increased their price target on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Truist Financial raised their target price on shares of Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, November 25th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Scholar Rock has an average rating of “Buy” and a consensus price target of $40.86.

Scholar Rock Price Performance

Shares of NASDAQ:SRRK opened at $33.28 on Tuesday. The stock has a market capitalization of $3.15 billion, a P/E ratio of -14.16 and a beta of 0.59. The business has a 50-day moving average of $38.40 and a two-hundred day moving average of $32.72. Scholar Rock has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Insider Transactions at Scholar Rock

In other Scholar Rock news, Director Katie Peng sold 1,006 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $34.42, for a total value of $34,626.52. Following the sale, the director now directly owns 30,319 shares in the company, valued at $1,043,579.98. This trade represents a 3.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Edward H. Myles sold 12,539 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $554,223.80. Following the transaction, the chief financial officer now directly owns 148,549 shares of the company’s stock, valued at $6,565,865.80. This represents a 7.78 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 299,772 shares of company stock worth $11,245,798. Insiders own 19.20% of the company’s stock.

Institutional Trading of Scholar Rock

Institutional investors have recently modified their holdings of the company. GAMMA Investing LLC raised its stake in shares of Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after purchasing an additional 269 shares in the last quarter. Quarry LP increased its holdings in Scholar Rock by 3,443.3% in the 3rd quarter. Quarry LP now owns 4,500 shares of the company’s stock valued at $36,000 after buying an additional 4,373 shares during the period. Global Retirement Partners LLC raised its stake in shares of Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after buying an additional 766 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after acquiring an additional 1,031 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Scholar Rock during the 4th quarter valued at about $85,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.